The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications

References

• Carracher AM, Marathe PH, Close KL. American association of diabetes educators. J Diabetes. 2017;9(12):1054–1057. doi:10.1111/1753-0407.12603
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
   PubMed Web of Science ®Google Scholar
• Ying W, Fu W, Lee YS, Olefsky JM. The role of macrophages in obesity-associated islet inflammation and β-cell abnormalities. Nat Rev Endocrinol. 2020;16(2):81–90. doi:10.1038/s41574-019-0286-3
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113(9):1009–1023. doi:10.1093/cvr/cvx108
   PubMed Web of Science ®Google Scholar
• von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. Current and future therapies for type 1 diabetes. Diabetologia. 2021;64(5):1037–1048. doi:10.1007/s00125-021-05398-3
   PubMed Web of Science ®Google Scholar
• Esser N, Lhomme L, De RA, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia. 2013;56(11):2487–2497. doi:10.1007/s00125-013-3023-9
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1–4. doi:10.1172/JCI92035
   PubMed Web of Science ®Google Scholar
• Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–3025. doi:10.1172/JCI28898
   PubMed Web of Science ®Google Scholar
• Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res. 2017;113(4):389–398. doi:10.1093/cvr/cvx012
   PubMed Web of Science ®Google Scholar
• Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005;437(7059):759–763. doi:10.1038/nature03988
   PubMed Web of Science ®Google Scholar
• Cameron AR, Morrison VL, Levin D, et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016;119(5):652–665. doi:10.1161/CIRCRESAHA.116.308445
   PubMed Web of Science ®Google Scholar
• Kim SC, Wu S, Fang X, et al. Postconditioning with a CpG containing oligodeoxynucleotide ameliorates myocardial infarction in a murine closed-chest model. Life Sci. 2014;119(1–2):1–8. doi:10.1016/j.lfs.2014.09.029
   PubMed Web of Science ®Google Scholar
• Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D. 2016;16(3):255–261. doi:10.1007/s40268-016-0137-9
   PubMedGoogle Scholar
• Ruscitti P, Masedu F, Alvaro S, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, open-label, randomised controlled trial. PLoS Med. 2019;16(9):e1002901. doi:10.1371/journal.pmed.1002901
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of Interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71(21):2405–2414. doi:10.1016/j.jacc.2018.03.490
   PubMed Web of Science ®Google Scholar
• Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392–2401. doi:10.1016/j.jacc.2018.03.002
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao H, Luo Y. Anti-aging implications of Astragalus Membranaceus (Huangqi): a well-known Chinese tonic. Aging Dis. 2017;8(6):868–886. doi:10.14336/AD.2017.0816
   PubMed Web of Science ®Google Scholar
• Fu TX, Wu GL. Effect of Astragalus injection on inflammatory mediators and the expression of adiponectin in renal tissue of rats with diabetic nephropathy. Chin J Clin Pharmacol. 2019;35(2):150–153. Chinese.
   Google Scholar
• Chen MM, Jia JH, Tan YJ, et al. Shen-Qi-Jiang-Tang granule ameliorates diabetic nephropathy via modulating tumor necrosis factor signaling pathway. J Ethnopharmacol. 2023;303:116031. doi:10.1016/j.jep.2022.116031
   PubMed Web of Science ®Google Scholar
• Tan YQ, Chen HW, Li J. Astragaloside IV: an effective drug for the treatment of cardiovascular diseases. Drug Des Devel Ther. 2020;14:3731–3746. doi:10.2147/DDDT.S272355
   PubMed Web of Science ®Google Scholar
• Wu Y, Fan Z, Chen Z, et al. Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a. Mol Cell Biochem. 2020;470(1–2):41–51. doi:10.1007/s11010-020-03743-5
   PubMed Web of Science ®Google Scholar
• Shi H, Zhou P, Gao G, et al. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway. J Food Biochem. 2021;45(7):e13757. doi:10.1111/jfbc.13757
   PubMed Web of Science ®Google Scholar
• Yang L, Xing F, Han X, et al. Astragaloside IV regulates differentiation and induces apoptosis of activated CD4+ T cells in the pathogenesis of experimental autoimmune encephalomyelitis. Toxicol Appl Pharmacol. 2019;362:105–115. doi:10.1016/j.taap.2018.10.024
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang H, Lu M, et al. Astragaloside IV prevents myocardial hypertrophy induced by mechanical stress by activating autophagy and reducing inflammation. Am J Transl Res. 2020;12(9):5332–5342.
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang Y, Zeng S, Lu J, Jiang TM, Li YM. Protective effect of astragaloside IV on lipopolysaccharide-induced cardiac dysfunction via downregulation of inflammatory signaling in mice. Immunopharmacol Immunotoxicol. 2015;37(5):428–433. doi:10.3109/08923973.2015.1080266
   PubMed Web of Science ®Google Scholar
• Li M, Yu L, She T, et al. Astragaloside IV attenuates Toll-like receptor 4 expression via NF-κB pathway under high glucose condition in mesenchymal stem cells. Eur J Pharmacol. 2012;696(1–3):203–209. doi:10.1016/j.ejphar.2012.09.033
   PubMed Web of Science ®Google Scholar
• Chang YX, Sun YG, Li J, et al. The experimental study of Astragalus membranaceus on Meridian tropsim: the distribution study of astragaloside IV in rat tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;911:71–75. doi:10.1016/j.jchromb.2012.10.024
   PubMed Web of Science ®Google Scholar
• Du Y, Zhang Q, Chen GG, Wei P, Tu CY. Pharmacokinetics of Astragaloside IV in rats by liquid chromatography coupled with tandem mass spectrometry. Eur J Drug Metab Pharmacokinet. 2005;30(4):269–273. doi:10.1007/BF03190631
   PubMed Web of Science ®Google Scholar
• Li L, Hou X, Xu R, Liu C, Tu M. Research review on the pharmacological effects of astragaloside IV. Fundam Clin Pharmacol. 2017;31(1):17–36. doi:10.1111/fcp.12232
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhu LL, Chen GG, Du Y. Pharmacokinetics of astragaloside iv in beagle dogs. Eur J Drug Metab Pharmacokinet. 2007;32(2):75–79. doi:10.1007/BF03190995
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang C, Liu R, et al. Quantitative determination of Astragaloside IV, a natural product with cardioprotective activity, in plasma, urine and other biological samples by HPLC coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;822(1–2):170–177. doi:10.1016/j.jchromb.2005.05.034
   PubMed Web of Science ®Google Scholar
• Huang CR, Wang GJ, Wu XL, et al. Absorption enhancement study of astragaloside IV based on its transport mechanism in caco-2 cells. Eur J Drug Metab Pharmacokinet. 2006;31(1):5–10. doi:10.1007/BF03190635
   PubMed Web of Science ®Google Scholar
• Qing LS, Chen TB, Sun WX, et al. Pharmacokinetics comparison, intestinal absorption and acute toxicity assessment of a novel water-soluble astragaloside IV derivative (astragalosidic acid, LS-102). Eur J Drug Metab Pharmacokinet. 2019;44(2):251–259. doi:10.1007/s13318-018-0515-5
   PubMed Web of Science ®Google Scholar
• Zhang L, Li LZ, Gong HY. Chronic toxicity of Fufanghuangqi Capsula in experimental animals. Acta Acad Med CPAPF. 2005;2:108–110. Chinese.
   Google Scholar
• Yang YH, Chen YX, Ouyang HT, Cheng JP. Study on safety tests and acute toxicological test of lyophilized powder of Astragalus for injection. Acta Acad Med Xuzhou. 2007;2:88–91. Chinese.
   Google Scholar
• Ouyang HT, Yang JY, Yu SY, et al. Long-term toxicity studies of lyophilized powder of astragalus membranaceus extract in rats and dogs. Chin J Modern Med. 2008;15:2173–2175+2179. Chinese.
   Google Scholar
• Zhan GY, Sun JQ, Zhan J, Wang HQ. The toxicology research of astragalus membranaceus composite nutrient liquid. J Guiyang Med Coll. 1994;3:271–273. Chinese.
   Google Scholar
• Han R, Zhu LJ, Pan JX, Zhang KP. Acute and chronic toxicity studies of huangqi injection in mice and rats. Chin Wild Plant Res. 2004;4:50–53. Chinese.
   Google Scholar
• Yu SY, Ouyang HT, Yang JY, et al. Subchronic toxicity studies of Radix Astragali extract in rats and dogs. J Ethnopharmacol. 2007;110(2):352–355. doi:10.1016/j.jep.2006.09.024
   PubMed Web of Science ®Google Scholar
• Gui D, Guo Y, Wang F, et al. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One. 2012;7(6):e39824. doi:10.1371/journal.pone.0039824
   PubMed Web of Science ®Google Scholar
• Xuying W, Jiangbo Z, Yuping Z, et al. Effect of astragaloside IV on the general and peripartum reproductive toxicity in Sprague-Dawley rats. Int J Toxicol. 2010;29(5):505–516. doi:10.1177/1091581810376840
   PubMed Web of Science ®Google Scholar
• Jiang B, Yang Y, Jin H, et al. Astragaloside IV attenuates lipolysis and improves insulin resistance induced by TNFalpha in 3T3-L1 adipocytes. Phytother Res. 2008;22(11):1434–1439. doi:10.1002/ptr.2434
   PubMed Web of Science ®Google Scholar
• Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430–15435. doi:10.1073/pnas.0904944106
   PubMed Web of Science ®Google Scholar
• Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134(5):1369–1375. doi:10.1053/j.gastro.2008.01.075
   PubMed Web of Science ®Google Scholar
• Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity. 2010;18(8):1510–1515. doi:10.1038/oby.2010.90
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang LL, Tang WJ, Tang B. Astragaloside IV inhibits protein tyrosine phosphatase 1B and improves insulin resistance in insulin-resistant HepG2 cells and triglyceride accumulation in oleic acid (OA)-treated HepG2 cells. J Ethnopharmacol. 2021;268:113556. doi:10.1016/j.jep.2020.113556
   PubMed Web of Science ®Google Scholar
• Huang L, Yue P, Wu X, et al. Combined intervention of swimming plus metformin ameliorates the insulin resistance and impaired lipid metabolism in murine gestational diabetes mellitus. PLoS One. 2018;13(4):e0195609. doi:10.1371/journal.pone.0195609
   PubMed Web of Science ®Google Scholar
• Wei X, Gu N, Feng N, Guo X, Ma X. Inhibition of p38 mitogen-activated protein kinase exerts a hypoglycemic effect by improving β cell function via inhibition of β cell apoptosis in db/db mice. J Enzyme Inhib Med Chem. 2018;33(1):1494–1500. doi:10.1080/14756366.2018.1477138
   PubMed Web of Science ®Google Scholar
• Lv L, Wu SY, Wang GF, et al. Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Phytother Res. 2010;24(2):219–224. doi:10.1002/ptr.2915
   PubMed Web of Science ®Google Scholar
• Zhu R, Zheng J, Chen L, Gu B, Huang S. Astragaloside IV facilitates glucose transport in C2C12 myotubes through the IRS1/AKT pathway and suppresses the palmitate-induced activation of the IKK/IκBα pathway. Int J Mol Med. 2016;37(6):1697–1705. doi:10.3892/ijmm.2016.2555
   PubMed Web of Science ®Google Scholar
• Böni-Schnetzler M, Meier DT. Islet inflammation in type 2 diabetes. Semin Immunopathol. 2019;41(4):501–513. doi:10.1007/s00281-019-00745-4
   PubMed Web of Science ®Google Scholar
• Zhang N, Wang XH, Mao SL, Zhao F. Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats. Molecules. 2011;16(5):3896–3907. doi:10.3390/molecules16053896
   PubMed Web of Science ®Google Scholar
• Leng B, Tang F, Lu M, Zhang Z, Wang H, Zhang Y. Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Life Sci. 2018;209:111–121. doi:10.1016/j.lfs.2018.07.053
   PubMed Web of Science ®Google Scholar
• Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thromb Haemost. 2003;90(5):904–914. doi:10.1160/TH03-03-0136
   PubMed Web of Science ®Google Scholar
• Leng B, Li C, Sun Y, et al. Protective effect of astragaloside IV on high glucose-induced endothelial dysfunction via inhibition of P2X7R dependent P38 MAPK signaling pathway. Oxid Med Cell Longev. 2020;2020:5070415. doi:10.1155/2020/5070415
   PubMed Web of Science ®Google Scholar
• You L, Fang Z, Shen G, et al. Astragaloside IV prevents high glucose-induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells. Mol Med Rep. 2019;19(3):1603–1612. doi:10.3892/mmr.2019.9812
   PubMed Web of Science ®Google Scholar
• Xu ME, Xiao SZ, Sun YH, Ou-Yang Y, Zheng XX. Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro. Acta Pharmacol Sin. 2006;27(2):229–236. doi:10.1111/j.1745-7254.2006.00243.x
   PubMed Web of Science ®Google Scholar
• Ma Y, Li W, Yin Y, Li W. AST IV inhibits H2O2-induced human umbilical vein endothelial cell apoptosis by suppressing Nox4 expression through the TGF-β1/Smad2 pathway. Int J Mol Med. 2015;35(6):1667–1674. doi:10.3892/ijmm.2015.2188
   PubMed Web of Science ®Google Scholar
• Qian W, Qian Q, Cai X, et al. Astragaloside IV inhibits oxidized low-density lipoprotein-induced endothelial damage via upregulation of miR-140-3p. Int J Mol Med. 2019;44(3):847–856. doi:10.3892/ijmm.2019.4257
   PubMed Web of Science ®Google Scholar
• Reglero-Real N, Colom B, Bodkin JV, Nourshargh S. Endothelial cell junctional adhesion molecules: role and regulation of expression in inflammation. Arterioscler Thromb Vasc Biol. 2016;36(10):2048–2057. doi:10.1161/ATVBAHA.116.307610
   PubMed Web of Science ®Google Scholar
• Li HB, Ge YK, Zhang L, Zheng XX. Astragaloside IV improved barrier dysfunction induced by acute high glucose in human umbilical vein endothelial cells. Life Sci. 2006;79(12):1186–1193. doi:10.1016/j.lfs.2006.03.041
   PubMed Web of Science ®Google Scholar
• Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702. doi:10.1161/CIRCRESAHA.115.306361
   PubMed Web of Science ®Google Scholar
• Hénaut L, Mary A, Chillon JM, Kamel S, Massy ZA. The impact of uremic toxins on vascular smooth muscle cell function. Toxins. 2018;10(6):218. doi:10.3390/toxins10060218
   PubMed Web of Science ®Google Scholar
• Yuan W, Zhang Y, Ge Y, Yan M, Kuang R, Zheng X. Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro. Planta Med. 2008;74(10):1259–1264. doi:10.1055/s-2008-1081290
   PubMed Web of Science ®Google Scholar
• Zhang X, Fu Y, Li H, et al. H3 relaxin inhibits the collagen synthesis via ROS- and P2X7R-mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose. J Cell Mol Med. 2018;22(3):1816–1825. doi:10.1111/jcmm.13464
   PubMed Web of Science ®Google Scholar
• Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol. 2018;68–69:490–506. doi:10.1016/j.matbio.2018.01.013
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu Y, Zhang Y, et al. Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM. Biomed Pharmacother. 2020;127:110081. doi:10.1016/j.biopha.2020.110081
   PubMed Web of Science ®Google Scholar
• Vernier M, Giguère V. Aging, senescence and mitochondria: the PGC-1/ERR axis. J Mol Endocrinol. 2021;66(1):R1–R14. doi:10.1530/JME-20-0196
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Zhu Y, Zhang H, Wang H. Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism. Mol Med Rep. 2019;20(5):4612–4622. doi:10.3892/mmr.2019.10716
   PubMed Web of Science ®Google Scholar
• Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, et al. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin Investig Drugs. 2016;25(9):1045–1058. doi:10.1080/13543784.2016.1196184
   PubMed Web of Science ®Google Scholar
• Saoud R, Jaffa MA, Habib A, et al. Modulation of proteomic and inflammatory signals by Bradykinin in podocytes. J Adv Res. 2020;24:409–422. doi:10.1016/j.jare.2020.05.021
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL, Cherney DZI. The new biology of diabetic kidney disease-mechanisms and therapeutic implications. Endocr Rev. 2020;41(2):202–231. doi:10.1210/endrev/bnz010
   PubMed Web of Science ®Google Scholar
• Gui D, Huang J, Guo Y, et al. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression. Cytokine. 2013;61(3):970–977. doi:10.1016/j.cyto.2013.01.008
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin C, Ren Q, Liu Y, Yang X. Astragaloside effect on TGF-β1, SMAD2/3, and α-SMA expression in the kidney tissues of diabetic KKAy mice. Int J Clin Exp Pathol. 2015;8(6):6828–6834.
   PubMed Web of Science ®Google Scholar
• Zhan H, Han P, Wang M, et al. Combination of astragaloside IV and ACEi ameliorates renal injuries in db/db mice. Int J Clin Exp Pathol. 2020;13(5):827–836.
   PubMed Web of Science ®Google Scholar
• Lei X, Zhang BD, Ren JG, Luo FL. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway. Life Sci. 2018;206:77–83. doi:10.1016/j.lfs.2018.05.037
   PubMed Web of Science ®Google Scholar
• Chen Y, Gui D, Chen J, He D, Luo Y, Wang N. Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol Biochem. 2014;33(6):1975–1987. doi:10.1159/000362974
   PubMedGoogle Scholar
• Wang ZS, Xiong F, Xie XH, Chen D, Pan JH, Cheng L. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrol. 2015;16:44. doi:10.1186/s12882-015-0031-7
   PubMed Web of Science ®Google Scholar
• Yao XM, Liu YJ, Wang YM, et al. Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6. Mol Med Rep. 2016;13(6):5149–5156. doi:10.3892/mmr.2016.5167
   PubMed Web of Science ®Google Scholar
• Menne J, Eulberg D, Beyer D, et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant. 2017;32(2):307–315. doi:10.1093/ndt/gfv459
   PubMed Web of Science ®Google Scholar
• Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119(6):1438–1449. doi:10.1172/JCI38019
   PubMed Web of Science ®Google Scholar
• Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21(2):212–222. doi:10.1681/ASN.2008121226
   PubMed Web of Science ®Google Scholar
• Chen J, Gui D, Chen Y, Mou L, Liu Y, Huang J. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition. Biochem Pharmacol. 2008;76(6):796–804. doi:10.1016/j.bcp.2008.06.020
   PubMed Web of Science ®Google Scholar
• Sun L, Li W, Li W, Xiong L, Li G, Ma R. Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions. Int J Mol Med. 2014;34(1):167–176. doi:10.3892/ijmm.2014.1741
   PubMed Web of Science ®Google Scholar
• Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16(4):206–222. doi:10.1038/s41581-019-0234-4
   PubMed Web of Science ®Google Scholar
• Chung S, Overstreet JM, Li Y, et al. TGF-β promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight. 2018;3(21):e123563. doi:10.1172/jci.insight.123563
   PubMed Web of Science ®Google Scholar
• Chen X, Yang Y, Liu C, Chen Z, Wang D. Astragaloside IV ameliorates high glucose-induced renal tubular epithelial-mesenchymal transition by blocking mTORC1/p70S6K signaling in HK-2 cells. Int J Mol Med. 2019;43(2):709–716. doi:10.3892/ijmm.2018.3999
   PubMed Web of Science ®Google Scholar
• Wang YN, Zhao SL, Su YY, et al. Astragaloside IV attenuates high glucose-induced EMT by inhibiting the TGF-β/Smad pathway in renal proximal tubular epithelial cells. Biosci Rep. 2020;40(6):BSR20190987. doi:10.1042/BSR20190987
   PubMedGoogle Scholar
• Wang Q, Shao X, Xu W, et al. Astragalosides IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells. Ren Fail. 2014;36(3):400–406. doi:10.3109/0886022X.2013.867798
   PubMed Web of Science ®Google Scholar
• Wang T, Zhang Z, Song C, et al. Astragaloside IV protects retinal pigment epithelial cells from apoptosis by upregulating miR-128 expression in diabetic rats. Int J Mol Med. 2020;46(1):340–350. doi:10.3892/ijmm.2020.4588
   PubMed Web of Science ®Google Scholar
• Ding Y, Yuan S, Liu X, et al. Protective effects of astragaloside IV on db/db mice with diabetic retinopathy. PLoS One. 2014;9(11):e112207. doi:10.1371/journal.pone.0112207
   PubMed Web of Science ®Google Scholar
• Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93(6):1296–1313. doi:10.1016/j.neuron.2017.02.005
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang Y, Sun S, et al. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol. 2006;84(6):579–587. doi:10.1139/y06-015
   PubMed Web of Science ®Google Scholar
• Stino AM, Rumora AE, Kim B, Feldman EL. Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy. J Peripher Nerv Syst. 2020;25(2):76–84. doi:10.1111/jns.12387
   PubMed Web of Science ®Google Scholar
• Singh M, Kapoor A, McCracken J, Hill B, Bhatnagar A. Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages. Chem Biol Interact. 2017;265:16–23. doi:10.1016/j.cbi.2017.01.012
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound Healing: a Cellular Perspective. Physiol Rev. 2019;99(1):665–706. doi:10.1152/physrev.00067.2017
   PubMed Web of Science ®Google Scholar
• Boniakowski AM, denDekker AD, Davis FM, et al. SIRT3 regulates macrophage-mediated inflammation in diabetic wound repair. J Invest Dermatol. 2019;139(12):2528–2537.e2. doi:10.1016/j.jid.2019.05.017
   PubMed Web of Science ®Google Scholar
• Liu D, Yang P, Gao M, et al. NLRP3 activation induced by neutrophil extracellular traps sustains inflammatory response in the diabetic wound. Clin Sci. 2019;133(4):565–582. doi:10.1042/CS20180600
   PubMed Web of Science ®Google Scholar
• Salmaninejad A, Valilou SF, Soltani A, et al. Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol. 2019;42(5):591–608. doi:10.1007/s13402-019-00453-z
   PubMed Web of Science ®Google Scholar
• Luo X, Huang P, Yuan B, et al. Astragaloside IV enhances diabetic wound healing involving upregulation of alternatively activated macrophages. Int Immunopharmacol. 2016;35:22–28. doi:10.1016/j.intimp.2016.03.020
   PubMed Web of Science ®Google Scholar
• Zhang D, Huang Q. Encapsulation of astragaloside with matrix metalloproteinase-2-responsive hyaluronic acid end-conjugated polyamidoamine dendrimers improves wound healing in diabetes. J Biomed Nanotechnol. 2020;16(8):1229–1240. doi:10.1166/jbn.2020.2971
   PubMed Web of Science ®Google Scholar
• Huang SF, Xu L. Preparation of astrageloside IV nanomicelles and transport study in Caco-2 cell mode. Xibei Med J. 2022;37(2):94–98. Chinese.
   Google Scholar
• Lv S, Zhang W, Yuan P, Lu C, Dong J, Zhang J. QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy. Pharm Biol. 2022;60(1):722–728. doi:10.1080/13880209.2022.2056206
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wu C, Qian X, et al. Multitarget and multipathway regulation of zhenqi fuzheng granule against non-small cell lung cancer based on network pharmacology and molecular docking. Evid Based Complement Alternat Med. 2022;17(2022):5967078.
   Google Scholar
• Lin X, Wang Q, Sun S, et al. Astragaloside IV promotes the eNOS/NO/cGMP pathway and improves left ventricular diastolic function in rats with metabolic syndrome. J Int Med Res. 2020;48(1):300060519826848. doi:10.1177/0300060519826848
   PubMed Web of Science ®Google Scholar